Ratings Orexo AB OTC Markets

Equities

ORXOY

US68616W1027

Delayed OTC Markets Other stock markets 10:00:30 2024-05-06 am EDT			5-day change	1st Jan Change
1.65 ^USD	+17.86%		0.00%	+9.27%

May. 08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
Apr. 17	Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Weaknesses

Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OREXO AB	+9.27%	65.99M		-
KYOWA KIRIN CO. LTD.	+10.23%	9.11B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.21B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+53.60%	4.83B		-
YUHAN CORPORATION	+7.56%	4.09B		B-
BETTA PHARMACEUTICALS CO., LTD.	-21.42%	2.35B		C-
INDIVIOR PLC	+14.51%	2.32B		B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+25.03%	2.27B	-	-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-30.36%	2.19B		-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes